Bristol Myers reveals a pair of Phase 3 wins for fibrosis, RayzeBio drugs
Phase 3positiveadmilparantPositive
AI Analysis
Summary
Bristol Myers Squibb announced positive Phase 3 results for two fibrosis and RayzeBio programs, including admilparant for lung disease. The drug had previously faced safety concerns.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Two Phase 3 trials succeeded, including one for admilparant in lung disease
Importance:8/10
Sentiment:
0.80
Phase 3clinical trialfibrosislung diseaseBristol Myers SquibbRayzeBio
Related Companies
Read the original article
Published by Endpoints News on October 12, 2026 3:04 PM